2017 Company Overview

Published Wed Dec 20, 2017


2017: A year in reveiw for ArcherDX

BOULDER, CO - As 2017 comes to an end, we want to thank you for your engagement and enthusiasm in our quest to move the genomic healthcare revolution forward by addressing the bottlenecks associated with using next-generation sequencing assays. This year has proven to be exciting for ArcherDX, and we look forward to continuing this momentum into 2018. Check out some highlights below from the year in review.

ISO certification

We received our EN ISO 13485 certification indicating that Archer® products are routinely subjected to rigorous, independent testing to ensure standards specific to medical devices, including in vitro diagnostic (IVD) assays, are maintained. This critical certification will allow for the development of companion diagnostics (CDx) and other IVD assays while ensuring product performance and reliability.

Learn more.

Celgene collaboration

We entered into partnership with Celgene to develop and commercialize an NGS-based oncology CDx for their investigational drug CC-122 for use in Diffuse Large B Cell Lymphoma (DLBCL). This exciting collaboration affords us the opportunity to deliver on the promise of precision medicine.

Learn more.

Launch of new myeloid panels expands blood-based NGS assay portfolio

We launched two new NGS-based gene variant detection assays specific to myeloid malignancies - the 37-gene Archer VariantPlex® Core Myeloid Kit and the 75-gene VariantPlex Myeloid Kit. Both of these panels leverage molecular barcoded reads and state-of-the-art bioinformatics to deliver unprecedented confidence in detecting myeloid-specific mutations, including traditionally difficult targets such as FLT3-ITDs and CEBPa.

Learn more.

Launch of Immunoverse BCR kits

Complimenting Archer Immunoverse™ TCR kits, we launched Immunoverse BCR kits to amplify the B cell receptor heavy (IGH) and light (kappa/lambda) chains for many applications, including clonality assessment, clone tracking and somatic hypermutation detection.

Learn more.

Leaps and bounds in chemistry and software improvements

The Archer R&D team made big advances in the performance of VariantPlex, FusionPlex and Reveal ctDNA products. Chemistry and protocol optimizations ensured highly efficient capture and library preparation. Analysis 5.1 incorporated cutting-edge filters and techniques for error correction and background noise characterization on a per-variant basis to deliver highly confident mutation detection down to .1% AF.

Learn more.

Widespread Reveal ctDNA™ adoption

Our customers have demonstrated that Archer technology can improve NGS-based liquid biopsy mutation detection with molecular barcodes, preferential small-fragment enrichment and advanced bioinformatic filtering and noise reduction. Simple workflows and low read requirements have allowed even the smallest labs to analyze mutations from ctDNA.

Learn more.

Delivery of rapidly customizable and future-proof panels

Armed with a flexible technology, forward-thinking Archer-ites have shown an incredible capability to rapidly develop high-performance custom panels to customers all over the world. Even better, the panels allow for new additions without impacting the performance of the panel. Labs can now have panels that grow with them and match the pace of discovery.

Learn more.

2017 posters/publications

  • Archer technology was featured in 90 posters and 13 publications
Learn more.

2017 conferences

  • We attended 17 scientific conferences around the globe

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.